Nordic Nanovector ASA ( (DE:8NN) ) just unveiled an update.
Thor Medical ASA announced its interim and preliminary full-year 2024 results, highlighting its progress in the pre-commercial phase with plans to make a final investment decision for its AlphaOne plant by March 2025, aiming for a start-up in 2026. The company has begun delivering limited commercial volumes from its pilot plant and has secured several commercial agreements for its alpha-emitting isotopes, indicating strong market demand. The company successfully completed its pilot facilities, secured strategic sales agreements, and raised capital for the AlphaOne plant, ensuring full funding through its construction and ramp-up. These developments position Thor Medical well in the rapidly growing radiotherapeutics market, with plans to potentially increase production capacity to meet demand.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier of radionuclides, primarily focusing on alpha particle emitters derived from naturally occurring thorium. The company employs a proprietary production process that does not require irradiation or the use of nuclear reactors, offering a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is based in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
YTD Price Performance: -8.18%
Average Trading Volume: 6,099
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €66.97M
For detailed information about 8NN stock, go to TipRanks’ Stock Analysis page.